Patents related to Dengue Virus Infection
No Thumbnail Available
Authors
Warda, Mohamad
Marks, Rory M.
Linhardt, Robert J.
Issue Date
2002-08-01
Type
Article
Language
ENG
Keywords
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Alternative Title
Abstract
This review discusses patents relevant to dengue virus infection. Dengue virus is a mosquito-transmitted flavivirus that usually causes an acute self-limited febrile illness, but may result in more severe life threatening disease. The lack of animal models that replicate features of the human disease has inhibited developing an understanding of the pathophysiology of dengue virus infection and consequently, limited investigation into potential therapeutics. However, there has been considerable progress in vaccine development and recent insights into the identity of the cells infected during the course of dengue virus infection and characterisation of cell-surface receptors used to mediate infectivity, have provided important information with therapeutic implications. There is no treatment for dengue virus infection and no vaccine is yet available, new approaches are urgently needed.
Description
Expert Opinions on Therapeutic Patents, Expert Opinion, 12(8), 1127-1143
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Full Citation
Patents related to Dengue Virus Infection, M. Warda, R. M. Marks. R. J. Linhardt, Expert Opinions on Therapeutic Patents, Expert Opinion, 12(8), 1127-1143, 2002. .
Publisher
Terms of Use
Journal
Volume
Issue
PubMed ID
DOI
ISSN
13543776